How Pharmacovigilance industry has changed post covid

In a data-driven world, adopting technological innovation is not only beneficial, but also necessary to deliver on the promise of patient safety, treatment, and efficacy in the case of COVID-19. There’s a need for new technologies to collect all clinical trials data with manpower.

During the pandemic, the most challenging task for the pharmacovigilance sector was that they couldn’t travel and visit hospitals as usual to collect the AE data. To overcome this issue we are in need of a system ( i.e artificial intelligence) that can collect all the data anywhere and anytime.

The pandemic also alerted the FDA & various drug regulatory authorities of all the countries to strengthen their protocols related to drug safety and monitoring, these steps pushed the PV industry to develop new and more efficient methods for collecting clinical trials data.

The pharmacovigilance team of multi-national companies like “Parexel” had to switch to easy-to-use digital revenue forms, devices, and tablets for healthcare professionals to provide critical clinical trial data. The AI proved beneficial for administrative work, in the face of a massive influx of new data, AI-based technologies provided agile infrastructures that were more efficient and effective for the clinical investigators, healthcare providers, and the patients.  

The lesson that we learned from the ongoing pandemic is to develop a Digital Drug Safety Reporting System that includes an electronic system or paperless work for data collection and a robust intelligence responsive system to establish a better communication channel for analysis.